Guardant Health, Inc.

Nasdaq · Services-Medical Laboratories

Insider trades

Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Guardant Health develops blood-based liquid biopsy tests used to detect and monitor cancer, including products for therapy selection in advanced cancer patients and early cancer screening and recurrence monitoring. It sells laboratory testing services to oncologists and works with biopharmaceutical companies on companion diagnostics and clinical trial support.

Industry

Services-Medical Laboratories

Headquarters

Palo Alto, CA

Exchange

Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

Insider	Type	Value	Shares / Price	Date
Azar Alex M IIDirector	Sell	$11K	69at $159.89	Oct 14, 2026
Tariq MusaDirector	Sell	$18K	116at $156.45	Aug 17, 2026
Monroe Terilyn J.Chief People Officer	Sell	$2.20M	13,248at $166.11	Aug 12, 2026
Monroe Terilyn J.Chief People Officer	Sell	$3.14M	19,014at $165.16	Aug 12, 2026
Monroe Terilyn J.Chief People Officer	Sell	$1.63M	9,934at $164.27	Aug 12, 2026
Monroe Terilyn J.Chief People Officer	Sell	$605K	3,704at $163.41	Aug 12, 2026
Monroe Terilyn J.Chief People Officer	Sell	$67K	400at $167.92	Aug 12, 2026
Freeman ChrisChief Commercial Officer	Sell	$580K	3,463at $167.38	Aug 10, 2026
Freeman ChrisChief Commercial Officer	Sell	$1.24M	7,365at $168.79	Aug 10, 2026
Freeman ChrisChief Commercial Officer	Sell	$6.00M	35,364at $169.63	Aug 10, 2026
Freeman ChrisChief Commercial Officer	Sell	$2.96M	17,413at $170.24	Aug 10, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for GH.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable GH activity by email

Free alerts for the insider and congressional trades worth watching.

Email address

US mobile number (optional)

SMS is optional: we only save your number if you check the consent box and provide a valid number. US mobile numbers only.

By checking this box and submitting, I agree to receive recurring automated marketing text messages from MySmarTrend (Ramy LLC) at the mobile number provided, including market alerts, commentary, and offers for MySmarTrend products and subscriptions. Messages may begin when the SMS program launches. Message frequency varies. Message and data rates may apply. Consent is not a condition of purchase or email signup. Reply STOP to opt out or HELP for help once messaging begins. Before launch or at any time, contact privacy@mysmartrend.com to withdraw consent or get help. I agree to the SMS Terms and acknowledge the Privacy Policy.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.